Inj estrogen conjugate 25 mg
Products billed under this code include Premarin.
Payment limit per 25 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Premarin.
Payment limit per 25 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Premarin | Pfizer Inc | 00046-0749-05 | 1 | $402.131 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $402.131 | +$0.628 | 25 MG | Inj estrogen conjugate 25 mg | v1, posted September 17, 2026 |
| 3Q26 | $401.503 | +$9.785 | 25 MG | Inj estrogen conjugate 25 mg | v1, posted September 15, 2026 |
| 2Q26 | $391.718 | −$0.043 | 25 MG | Inj estrogen conjugate 25 mg | v1, posted September 15, 2026 |
| 1Q26 | $391.761 | −$0.302 | 25 MG | Inj estrogen conjugate 25 mg | v1, posted September 15, 2026 |
| 4Q25 | $392.063 | +$1.32 | 25 MG | Inj estrogen conjugate 25 mg | v1, posted September 8, 2026 |
| 3Q25 | $390.743 | +$7.856 | 25 MG | Inj estrogen conjugate 25 mg | v1, posted March 10, 2026 |
| 2Q25 | $382.887 | −$0.025 | 25 MG | Inj estrogen conjugate 25 mg | v1, posted March 10, 2026 |
| 1Q25 | $382.912 | +$0.126 | 25 MG | Inj estrogen conjugate 25 mg | v1, posted December 19, 2025 |
| 4Q24 | $382.786 | −$1.244 | 25 MG | Inj estrogen conjugate 25 mg | v1, posted June 11, 2025 |
| 3Q24 | $384.03 | +$11.663 | 25 MG | Inj estrogen conjugate 25 mg | v1, posted June 11, 2025 |
| 2Q24 | $372.367 | +$0.221 | 25 MG | Inj estrogen conjugate 25 mg | v1, posted March 11, 2025 |
| 1Q24 | $372.146 | −$0.33 | 25 MG | Inj estrogen conjugate 25 mg | v1, posted December 19, 2024 |
| 4Q23 | $372.476 | +$0.583 | 25 MG | Inj estrogen conjugate 25 mg | v1, posted October 10, 2024 |
| 3Q23 | $371.893 | +$16.112 | 25 MG | Inj estrogen conjugate 25 mg | v1, posted June 5, 2024 |
| 2Q23 | $355.781 | +$0.258 | 25 MG | Inj estrogen conjugate 25 mg | v1, posted February 23, 2024 |
| 1Q23 | $355.523 | +$0.032 | 25 MG | Inj estrogen conjugate 25 mg | v1, posted December 6, 2023 |
| 4Q22 | $355.491 | +$1.821 | 25 MG | Inj estrogen conjugate 25 mg | v1, posted June 22, 2023 |
| 3Q22 | $353.67 | +$12.178 | 25 MG | Inj estrogen conjugate 25 mg | v1, posted June 9, 2023 |
| 2Q22 | $341.492 | −$0.009 | 25 MG | Inj estrogen conjugate 25 mg | v1, posted December 14, 2022 |
| 1Q22 | $341.501 | +$0.045 | 25 MG | Inj estrogen conjugate 25 mg | v1, posted June 8, 2022 |
| 4Q21 | $341.456 | −$0.309 | 25 MG | Inj estrogen conjugate 25 mg | v1, posted June 2, 2022 |
| 3Q21 | $341.765 | +$16.306 | 25 MG | Inj estrogen conjugate 25 mg | v1, posted June 2, 2022 |
| 2Q21 | $325.459 | −$0.048 | 25 MG | Inj estrogen conjugate 25 mg | v1, posted March 1, 2022 |
| 1Q21 | $325.507 | – | 25 MG | Inj estrogen conjugate 25 mg | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.